Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | HPGDS | O60760 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 3/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20996663 | 0.96 | MAPT (0.36) | TRPV1HPGDSMAPTTACR3PROKR1 | |
| SCHEMBL20971816 | 0.91 | TRPV1 (0.35) | TRPV1HPGDSTACR3JAK2JAK1 | |
| SCHEMBL20971734 | 0.88 | HPGDS (0.38) | TRPV1HPGDSMAPTJAK2JAK1 | |
| SCHEMBL20971791 | 0.88 | JAK2 (0.36) | TRPV1HPGDSTACR3JAK2JAK1 | |
| SCHEMBL20971858 | 0.88 | CYP3A4 (0.37) | TRPV1HPGDSTACR3JAK2JAK1 | |
| SCHEMBL20971837 | 0.87 | GCK (0.33) | TRPV1HPGDSTACR3JAK2JAK1 | |
| SCHEMBL20971812 | 0.87 | PROKR1 (0.46) | TRPV1HPGDSPROKR1 | |
| SCHEMBL20997142 | 0.86 | HTR5A (0.36) | TRPV1HPGDSTACR3JAK2JAK1 | |
| SCHEMBL20996769 | 0.85 | JAK2 (0.35) | TRPV1HPGDSMAPTTACR3JAK2 | |
| SCHEMBL20996923 | 0.85 | TACR3 (0.31) | TRPV1TACR3PROKR1TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | claimed |
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | disclosed |
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | NDUFAB1, FH, MT-ND1 | TRPV1 3515/4885HPGDS 2964/4885MAPT 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.